Search details
1.
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Br J Haematol
; 194(1): 83-91, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33942292
2.
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Lancet
; 385(9980): 1873-83, 2015 May 09.
Article
in English
| MEDLINE | ID: mdl-25882396
3.
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Blood Adv
; 8(2): 388-398, 2024 01 23.
Article
in English
| MEDLINE | ID: mdl-38048391
4.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 41(8): 1600-1609, 2023 03 10.
Article
in English
| MEDLINE | ID: mdl-36413710
5.
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 41(8): 1590-1599, 2023 03 10.
Article
in English
| MEDLINE | ID: mdl-36599114
6.
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 37(15): 1285-1295, 2019 05 20.
Article
in English
| MEDLINE | ID: mdl-30901302
7.
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Leuk Lymphoma
; 58(5): 1084-1093, 2017 05.
Article
in English
| MEDLINE | ID: mdl-27731748
8.
Assessment of the effect of ofatumumab on cardiac repolarization.
J Clin Pharmacol
; 55(1): 114-21, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25103870
Results
1 -
8
de 8
1
Next >
>>